Phosphodiesterase 7B1 as therapeutic target for treatment of cognitive dysfunctions in multiple sclerosis

Research paper by Arthi Balsundaram, Darling Chellathai

Indexed on: 21 Dec '18Published on: 18 Dec '18Published in: Journal of pharmacology & pharmacotherapeutics


Arthi Balsundaram, Darling Chellathai Journal of Pharmacology and Pharmacotherapeutics 2018 9(3):126-130 Multiple sclerosis (MS) is an autoimmune, chronic degenerative neuroinflammatory disorder affecting younger age groups of the United States of America and Europe. MS prevalence studies in India have shown that India is no longer a low-risk zone. Many studies have shown the seriousness of cognitive impairments (CIs) and its types caused in MS. In this review, the pathological basis for CI in various stages of MS was reviewed and revealed to provide a basis for the treatment. Role of phosphodiesterase 7B1 (PDE7B1) inhibitors in treating CI related to MS were also stated in this review. The literature for this review was collected from PubMed and Embase.